NCT06937060: SEMPSO

Effect of Semaglutide in Patients With Psoriasis and Obesity

Recruiting now Phase 3 Last updated 13 May 2025

What this trial tests

Phase 3 trial testing semaglutide in Psoriasis (PsO) in 14 participants. Currently enrolling.

Timeline

20 March 2025

Primary endpoint
31 July 2026

31 January 2027

Quick facts

Lead sponsor	The University of Hong Kong
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	20 March 2025
Primary completion	31 July 2026
Estimated completion	31 January 2027
Sites	1 location across Hong Kong

Drugs / interventions tested

• semaglutide (semaglutide) — full drug profile →

Conditions studied

• Psoriasis (PsO) — all drugs for Psoriasis (PsO) →
• Obesity and Overweight — all drugs for Obesity and Overweight →

Sponsor

The University of Hong Kong

Who can join

Adults 18 to 75, any sex, with Psoriasis (PsO) or Obesity and Overweight. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Obesity is well known to be an important comorbidity of psoriasis. It gives rise to higher risk of psoriatic arthritis, more severe disease and also poorer response to biologics. Weight loss can lead to reduction in psoriasis severity. Previous studies had demonstrated the efficacy of older glucagon-like peptide-1 receptor agonist (GLP1 RA) on improvement of psoriatic disease activity. Effective weight loss has been achieved by newer GLP1 RA.7 It is also known to reduce cardiovascular outcomes in patient without diabetes. Trials on the effect of semaglutide on psoriasis has not been performed except case reports.

Semaglutide is an injectable prescription medicine that may help adults and children aged 12 years and older with obesity or some adults with excess weight (overweight) who also have weight-related medical problem to help them lose weight. It contains a GLP1 RA indicated as an adjunct to diet and exercise to improve glycemic control. It has potential anti-inflammatory effects on top of weight reduction, that may lead to improvement in psoriatic disease activity.

This is an open-label, single-armed, prospective pilot trial on obese, psoriasis patients. The investigators aim to recruit 14 patients. Patients will be maintained on standard care for their psoriasis. Add-on treatment with semaglutide of up to 2.0mg per week will be administered to the intervention arm in addition to lifestyle intervention. Treatment with previous systemic immunosuppressants is allowed.

The maximum study duration for a single subject in the study will be approximately 36 weeks, 4 weeks of screening, 24-week treatment period, and a 12-week safety follow up period after the last study dose of semaglutide at week 24.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities.
   Ciancio G, Maranini B, Sandri G, Amati G, et al · · 2026 · PMID 42131335 · DOI 10.3389/fimmu.2026.1744308